TRICARE beneficiaries taking certain maintenance drugs for diabetes or high cholesterol are now paying lower or no copayments as part of a pilot program.
The Medication Adherence Pilot Program, launched on Feb. 1, will examine whether people are more likely to follow a medication treatment plan when those drugs are available at no-or-reduced cost. The program affects prescriptions purchased at in-network retail pharmacies and through the TRICARE Pharmacy Home Delivery.
“Patients who take their medications as prescribed enjoy improved health outcomes compared to those who don’t,” said U.S. Air Force Lt. Col. Ann McManis, Pharmacy Operation Division at the Defense Health Agency. “We’re excited to offer this program to beneficiaries who are living with these common, chronic conditions.”
The Defense Health Agency (DHA) chose two high-value medications for the pilot program: Lantus® Pens, an insulin shot to manage diabetes, and rosuvastatin, the generic version of Crestor®, to manage high cholesterol. Lantus Pens will be offered at reduced cost. Rosuvastatin will be offered at no cost at a retail network pharmacy and through home delivery.
Participation is automatic. DHA authorized the pilot program to run for up to five years.
Learn more about the TRICARE Pharmacy Program.